1
|
McKeown BT, Relja NJ, Hall SR, Gebremeskel S, MacLeod JM, Veinotte CJ, Bennett LG, Ohlund LB, Sleno L, Jakeman DL, Berman JN, Johnston B, Goralski KB. Pilot study of jadomycin B pharmacokinetics and anti-tumoral effects in zebrafish larvae and mouse breast cancer xenograft models. Can J Physiol Pharmacol 2022; 100:1065-1076. [PMID: 35985040 DOI: 10.1139/cjpp-2022-0152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Despite numerous therapeutic options, multidrug resistance (MDR) remains an obstacle to successful breast cancer therapy. Jadomycin B, a natural product derived from Streptomyces venezuelae ISP5230, maintains cytotoxicity in MDR human breast cancer cells. Our objectives were to evaluate the pharmacokinetics, toxicity, anti-tumoral, and anti-metastatic effects of jadomycin B in zebrafish larvae and mice. In a zebrafish larval xenograft model, jadomycin B significantly reduced the proliferation of human MDA-MB-231 cells at or below its maximum tolerated dose (40 µm). In female Balb/C mice, a single intraperitoneal dose (6 mg/kg) was rapidly absorbed with a maximum serum concentration of 3.4 ± 0.27 µm. Jadomycin B concentrations declined biphasically with an elimination half-life of 1.7 ± 0.058 h. In the 4T1 mouse mammary carcinoma model, jadomycin B (12 mg/kg every 12 h from day 6 to 15 after tumor cell injection) decreased primary tumor volume compared to vehicle control. Jadomycin B-treated mice did not exhibit weight loss, nor significant increases in biomarkers of impaired hepatic (alanine aminotransferase) and renal (creatinine) function. In conclusion, jadomycin B demonstrated a good safety profile and provided partial anti-tumoral effects, warranting further dose-escalation safety and efficacy studies in MDR breast cancer models.
Collapse
Affiliation(s)
- Brendan T McKeown
- Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.,Beatrice Hunter Cancer Research Institute, Halifax, NS, B3H 4R2, Canada
| | - Nicholas J Relja
- Faculty of Health, College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Steven R Hall
- Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Simon Gebremeskel
- Department of Microbiology & Immunology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Jeanna M MacLeod
- Faculty of Health, College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Chansey J Veinotte
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, IWK Health Centre, Halifax, NS, B3K 6R8, Canada
| | - Leah G Bennett
- Faculty of Health, College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Leanne B Ohlund
- Chemistry department/CERMO-FC, Faculty of Sciences, Université du Québec à Montréal, Montréal, QC, H2X 2J6, Canada
| | - Lekha Sleno
- Chemistry department/CERMO-FC, Faculty of Sciences, Université du Québec à Montréal, Montréal, QC, H2X 2J6, Canada
| | - David L Jakeman
- Faculty of Health, College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada.,Department of Chemistry, Faculty of Science, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Jason N Berman
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, IWK Health Centre, Halifax, NS, B3K 6R8, Canada.,Children's Hospital of Eastern Ontario Research Institute and Department of Pediatrics, University of Ottawa, Ottawa, ON, K1H 5B2, Canada.,Department of Pediatrics, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Brent Johnston
- Beatrice Hunter Cancer Research Institute, Halifax, NS, B3H 4R2, Canada.,Department of Microbiology & Immunology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.,Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Kerry B Goralski
- Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.,Beatrice Hunter Cancer Research Institute, Halifax, NS, B3H 4R2, Canada.,Faculty of Health, College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada.,Division of Pediatric Hematology/Oncology, Department of Pediatrics, IWK Health Centre, Halifax, NS, B3K 6R8, Canada
| |
Collapse
|
2
|
Bonitto EP, McKeown BT, Goralski KB. Jadomycins: A potential chemotherapy for multi-drug resistant metastatic breast cancer. Pharmacol Res Perspect 2021; 9:e00886. [PMID: 34708587 PMCID: PMC8551564 DOI: 10.1002/prp2.886] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 09/30/2021] [Indexed: 12/24/2022] Open
Abstract
Breast cancer causes the most cancer fatalities in women worldwide. Approximately one-third of breast cancers metastasize, or spread from primary tumors to other tissues, and have a 70% 5-year mortality rate. Current breast cancer treatments like doxorubicin and paclitaxel become ineffective when breast cancer cells develop multi-drug resistance and overexpress ATP-binding cassette transporters, as the transporters cause a substantial efflux of the chemotherapies. Jadomycins, a group of molecules isolated from Streptomyces venezuelae ISP5230, are shown to be cytotoxic against a variety of cancers, especially breast cancer. Furthermore, jadomycins retain their cytotoxic properties in multi-drug resistant breast cancer cells, as they are not expelled through ATP-binding cassette transporters. Here, we describe the research that supports the potential use of jadomycins as a novel chemotherapy in the treatment of multi-drug resistant, metastatic breast cancer. We present the supportive findings, as well as the mechanisms of action investigated thus far. These include copper-mediated reactive oxygen species generation, aurora B kinase inhibition, and topoisomerase IIα and IIβ inhibition. We also suggest future directions of jadomycin research, which will help to determine if jadomycins can be used as a breast cancer chemotherapy in clinical practice.
Collapse
Affiliation(s)
- Esther P. Bonitto
- Department of PharmacologyDalhousie UniversityHalifaxNova ScotiaCanada
| | - Brendan T. McKeown
- Department of PharmacologyDalhousie UniversityHalifaxNova ScotiaCanada
- Beatrice Hunter Cancer Research InstituteHalifaxNova ScotiaCanada
| | - Kerry B. Goralski
- Department of PharmacologyDalhousie UniversityHalifaxNova ScotiaCanada
- Beatrice Hunter Cancer Research InstituteHalifaxNova ScotiaCanada
- College of PharmacyDalhousie UniversityHalifaxNova ScotiaCanada
- Department of PediatricsDalhousie UniversityHalifaxNova ScotiaCanada
| |
Collapse
|
3
|
de Koning CB, Ngwira KJ, Rousseau AL. Biosynthesis, synthetic studies, and biological activities of the jadomycin alkaloids and related analogues. THE ALKALOIDS. CHEMISTRY AND BIOLOGY 2020; 84:125-199. [PMID: 32416952 DOI: 10.1016/bs.alkal.2020.02.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The jadomycins are an expanding class of compounds produced from Streptomyces venezuelae, by diverting the normal biosynthesis which provides the antibiotic chloramphenicol. In the presence of amino acids, and either by heat shock, supplementation with ethanol, or when phage SV1 is added to the culture, the formation of substituted jadomycins and benzo[b]phenanthridines can be achieved. The first part of this review provides details of intermediates involved in the biosynthesis of the jadomycins and the related benzo[b]phenanthridines. Both the jadomycins and the benzo[b]phenanthridines share biosynthetic pathways with a large class of naturally occurring compounds known as the angucyclines. The biosynthetic pathways diverge when it is postulated that an intermediate quinone, such as 3-(2-formyl-6-hydroxy-4-methylphenyl)-8-hydroxy-1,4-naphthoquinone-2-carboxylic acid is formed. The quinone then undergoes reactions with amino acids and derivatives in the culture medium to ultimately afford a library of jadomycins and a few benzo[b]phenanthridines. The second part of the review initially details synthetic efforts toward the synthesis of the naturally occurring benzo[b]phenanthridine, phenanthroviridin, and then outlines methods that have been used to assemble a selection of jadomycins. Total syntheses of jadomycin A and B, derived from l-isoleucine, are described. In addition, the synthesis of the aglycon of jadomycins M, W, S, and T is outlined. These four jadomycins were derived from l-methionine, l-tryptophan, l-serine and l-threonine respectively. As a result of these synthetic efforts, the structures of jadomycin S and T have been revised. The third part of the review describes the reported antibacterial and anticancer activities of both the jadomycins and some naturally occurring benzo[b]phenanthridines.
Collapse
Affiliation(s)
- Charles B de Koning
- Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa.
| | - Kennedy J Ngwira
- Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa
| | - Amanda L Rousseau
- Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa
| |
Collapse
|
4
|
Paniak TJ, Kozlowski MC. Aerobic Catalyzed Oxidative Cross-Coupling of N, N-Disubstituted Anilines and Aminonaphthalenes with Phenols and Naphthols. Org Lett 2020; 22:1765-1770. [PMID: 32049541 DOI: 10.1021/acs.orglett.0c00046] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
The cross-coupling of N,N-dialkyl aniline and aminonaphthalenes with phenols and naphthols using a Cr-salen catalyst under aerobic conditions was developed. Notably, air serves as an effective oxidant affording products in high selectivity. Initial mechanistic studies suggest an outer-sphere oxidation of the aniline/aminonaphthalene partner, followed by nucleophilic attack of the phenol/naphthol. Single products were observed in most cases, whereas mixtures of C-C and C-O coupled products arose from reactions involving aminonapthalene and sterically unencumbered phenols.
Collapse
Affiliation(s)
- Thomas J Paniak
- Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| | - Marisa C Kozlowski
- Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| |
Collapse
|
5
|
Forget SM, Robertson AW, Hall SR, MacLeod JM, Overy DP, Kerr RG, Goralski KB, Jakeman DL. Isolation of a jadomycin incorporating L-ornithine, analysis of antimicrobial activity and jadomycin reactive oxygen species (ROS) generation in MDA-MB-231 breast cancer cells. J Antibiot (Tokyo) 2018; 71:722-730. [PMID: 29700425 DOI: 10.1038/s41429-018-0060-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 03/01/2018] [Accepted: 04/02/2018] [Indexed: 02/01/2023]
Abstract
Herein, we report the characterization and antimicrobial activity of a previously unreported jadomycin (1) obtained from a culture of S. venezuelae ISP5230 with L-ornithine (Orn). 1 arises from the rearrangement of a putative five-membered ring containing jadomycin incorporating Orn, whereby intramolecular attack of the E-ring carbonyl from the δ-NH2 group of the Orn side chain results in collapse of the oxazolone ring and formation of a stable six-membered lactam. This rearrangement produces a jadomycin with a 3a hemiaminal position that is susceptible to solvolysis. A structure-activity relationship is discussed based on the antimicrobial activity of 1 compared to previously reported jadomycins, providing evidence that the presence of a 3a hemiaminal enhances activity against Gram-positive bacteria. Additionally, assays to quantify reactive oxygen species (ROS) generation and cell viability were performed using a series of nine jadomycins. Compound 1 was found to produce the highest ROS activity and to possess the greatest cytotoxicity against MDA-MB-231 breast cancer cells.
Collapse
Affiliation(s)
- Stephanie M Forget
- Department of Chemistry, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Andrew W Robertson
- Department of Chemistry, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Steven R Hall
- College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - Jeanna M MacLeod
- College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - David P Overy
- Department of Chemistry, University of Prince Edward Island, Charlottetown, PE, C1A 4P3, Canada
| | - Russell G Kerr
- Department of Chemistry, University of Prince Edward Island, Charlottetown, PE, C1A 4P3, Canada
| | - Kerry B Goralski
- College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada
| | - David L Jakeman
- Department of Chemistry, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
- College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
| |
Collapse
|